December 2025 in “Journal of Dermatological Treatment” GT20029 helps regrow hair in men with hair loss and is well-tolerated.
3 citations
,
August 2010 in “Letters in Drug Design & Discovery”
22 citations
,
November 2005 in “BMC Cancer” Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.
148 citations
,
April 2009 in “Molecular Pharmaceutics” Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
The microenvironment affects the behavior and survival of melanocytes with the GNAQ oncogene in melanoma.
January 2008 in “프로그램북(구 초록집)” 3 citations
,
January 2019 in “Annals of medical research” The conclusion cannot be provided because the document content is not available.
September 2023 in “Journal of The American Academy of Dermatology” The document's conclusion cannot be provided because the content is not available.
February 2017 in “Cancer Causes & Control” Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.
August 2023 in “Journal of Cosmetic Dermatology” QR678 Neo® improved seborrheic dermatitis symptoms in a small group of patients.
June 2023 in “BMC Pharmacology and Toxicology” The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.
April 2026 in “Frontiers in Medicine” Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.
7 citations
,
September 1997 in “PubMed” March 2025 in “SKIN The Journal of Cutaneous Medicine”
13 citations
,
September 2011 in “International Urology and Nephrology”
October 2010 in “International journal of radiation oncology, biology, physics” Two cycles of ABVD chemotherapy followed by 20 Gy radiotherapy is the new standard for early-stage Hodgkin lymphoma due to lower toxicity and similar effectiveness.
Topical GT20029 effectively promotes hair regrowth and is well-tolerated for treating androgenetic alopecia.
July 2022 in “British Journal of Dermatology” November 2025 in “Bioactive Materials” TQC shows promise for better hair regrowth in treating hair loss.
January 2024 in “Wiadomości Lekarskie” Patients with limited English prefer professional language interpretation in otolaryngology clinics.
December 2025 in “Chemical Engineering Journal” October 2024 in “Frontiers in Oncology” A new gene mutation linked to Olmsted syndrome may increase cancer risk, suggesting the need for ongoing patient monitoring.
111 citations
,
June 2015 in “Age and Ageing” Dutasteride, fesoterodine, and finasteride are beneficial for older patients, while most other drugs should be used cautiously or avoided.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
June 2011 in “Oncology times” New treatments are making advanced prostate cancer management more complex but also more hopeful.
October 2012 in “Sax's Dangerous Properties of Industrial Materials” 12 citations
,
January 2014 in “Journal of international medical research” Pemetrexed is as effective as docetaxel but has fewer side effects for treating nonsmall-cell lung cancer after EGFR-TKI therapy failure.
April 2012 in “The Journal of Urology” Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.